Frontier Biotechnologies Inc.

About Frontier Biotechnologies Inc.

Frontier Biotechnologies Inc. is a research-based pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing significant unmet medical needs. - Its lead product candidate ALBUVIRTIDE, a novel long-acting anti-HIV agent. - The second lead drug candidate AB001 is a third generation topical patch for the managemen...

  • CN
  • 2017
    On CPHI since
Contact info

Products from Frontier Biotechnologies Inc. (3)

  • Albuvirtide for injection - A Long-acting HIV Fusion Inhibitor

    Product Albuvirtide for injection - A Long-acting HIV Fusion Inhibitor

    The world’s first long acting HIV fusion inhibitor. An amino acid synthesized peptide, lyophilized powder for injection with shelf life 24 months. The API should be stored and transported at -20C, and the finished product should be stored and transported at 2-8C. ALBUVIRTIDE only need to be ad...
  • 3BNC117 - A Novel Broad-spectrum HIV Neutralizing Antibody

    Product 3BNC117 - A Novel Broad-spectrum HIV Neutralizing Antibody

    3BNC117 is one of the most effective broad-spectrum HIV neutralizing antibodies. Several phase 1 and phase 2 clinical trials have been conducted in the US, showing 3BNC117 not only blocks viral replication like other AIDS drugs, but also induces immune response to HIV and HIV-infected cells. Combining 3...
  • AB001 -A new transdermal patch for musculoskeletal

    Product AB001 -A new transdermal patch for musculoskeletal

    A third generation topical patch for the management of pain and inflammation. - Long half life; once daily dosage with relatively shorter administration period provides efficacy with less skin irritation/inflammation. - Patch is non-hydrogel, alcohol-free formulation.- Patch matrix formulation is onl...